Non-genetic Mechanisms of Therapeutic Resistance in Cancer

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2020 Oct 9

PMID 33033407

Citations 233

Authors

Jean-Christophe Marine

Sarah-Jane Dawson

Mark A Dawson

Affiliations

Soon will be listed here.

Abstract

Therapeutic resistance continues to be an indominable foe in our ambition for curative cancer treatment. Recent insights into the molecular determinants of acquired treatment resistance in the clinical and experimental setting have challenged the widely held view of sequential genetic evolution as the primary cause of resistance and brought into sharp focus a range of non-genetic adaptive mechanisms. Notably, the genetic landscape of the tumour and the non-genetic mechanisms used to escape therapy are frequently linked. Remarkably, whereas some oncogenic mutations allow the cancer cells to rapidly adapt their transcriptional and/or metabolic programme to meet and survive the therapeutic pressure, other oncogenic drivers convey an inherent cellular plasticity to the cancer cell enabling lineage switching and/or the evasion of anticancer immunosurveillance. The prevalence and diverse array of non-genetic resistance mechanisms pose a new challenge to the field that requires innovative strategies to monitor and counteract these adaptive processes. In this Perspective we discuss the key principles of non-genetic therapy resistance in cancer. We provide a perspective on the emerging data from clinical studies and sophisticated cancer models that have studied various non-genetic resistance pathways and highlight promising therapeutic avenues that may be used to negate and/or counteract the non-genetic adaptive pathways.

Citing Articles

ZEB1 transcription factor induces tumor cell PD-L1 expression in melanoma.

Wirbel C, Durand S, Boivin F, Plaschka M, Benboubker V, Grimont M Cancer Immunol Immunother. 2025; 74(4):141.

PMID: 40056177 PMC: 11890833. DOI: 10.1007/s00262-025-03978-5.

Molecular mechanisms altering cell identity in cancer.

Zippo A, Beyes S Oncogene. 2025; .

PMID: 40011573 DOI: 10.1038/s41388-025-03314-2.

Intratumour oxidative hotspots provide a niche for cancer cell dissemination.

Ueda Y, Kiyonaka S, Selfors L, Inoue K, Harada H, Doura T Nat Cell Biol. 2025; 27(3):530-543.

PMID: 39984655 DOI: 10.1038/s41556-025-01617-w.

EMT-driven plasticity prospectively increases cell-cell variability to promote therapeutic adaptation in breast cancer.

Muller L, Fauvet F, Chassot C, Angileri F, Coutant A, Degletagne C Cancer Cell Int. 2025; 25(1):32.

PMID: 39901189 PMC: 11789407. DOI: 10.1186/s12935-025-03637-w.

Early tolerance and late persistence as alternative drug responses in cancer.

Punzi S, Cittaro D, Gatti G, Crupi G, Botrugno O, Cartalemi A Nat Commun. 2025; 16(1):1291.

PMID: 39900637 PMC: 11790948. DOI: 10.1038/s41467-024-54728-7.

References

Scott A, Wolchok J, Old L . Antibody therapy of cancer. Nat Rev Cancer. 2012; 12(4):278-87. DOI: 10.1038/nrc3236. View

Mayes P, Hance K, Hoos A . The promise and challenges of immune agonist antibody development in cancer. Nat Rev Drug Discov. 2018; 17(7):509-527. DOI: 10.1038/nrd.2018.75. View

Smaglo B, Aldeghaither D, Weiner L . The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol. 2014; 11(11):637-48. PMC: 4700536. DOI: 10.1038/nrclinonc.2014.159. View

Meric-Bernstam F, Mills G . Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol. 2012; 9(9):542-8. DOI: 10.1038/nrclinonc.2012.127. View

Fong C, Gilan O, Lam E, Rubin A, Ftouni S, Tyler D . BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015; 525(7570):538-42. PMC: 6069604. DOI: 10.1038/nature14888. View

Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T . Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell. 2018; 173(4):879-893.e13. PMC: 6132060. DOI: 10.1016/j.cell.2018.03.041. View

Pisco A, Huang S . Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'. Br J Cancer. 2015; 112(11):1725-32. PMC: 4647245. DOI: 10.1038/bjc.2015.146. View

Shlush L, Mitchell A, Heisler L, Abelson S, Ng S, Trotman-Grant A . Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017; 547(7661):104-108. DOI: 10.1038/nature22993. View

Hugo W, Shi H, Sun L, Piva M, Song C, Kong X . Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015; 162(6):1271-85. PMC: 4821508. DOI: 10.1016/j.cell.2015.07.061. View

10.

Dobson S, Garcia-Prat L, Vanner R, Wintersinger J, Waanders E, Gu Z . Relapse-Fated Latent Diagnosis Subclones in Acute B Lineage Leukemia Are Drug Tolerant and Possess Distinct Metabolic Programs. Cancer Discov. 2020; 10(4):568-587. PMC: 7122013. DOI: 10.1158/2159-8290.CD-19-1059. View

11.

DeNicola G, Karreth F, Humpton T, Gopinathan A, Wei C, Frese K . Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011; 475(7354):106-9. PMC: 3404470. DOI: 10.1038/nature10189. View

12.

Nakasone E, Askautrud H, Kees T, Park J, Plaks V, Ewald A . Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012; 21(4):488-503. PMC: 3332002. DOI: 10.1016/j.ccr.2012.02.017. View

13.

Rosenzweig S . Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol. 2012; 83(8):1041-8. PMC: 3299940. DOI: 10.1016/j.bcp.2011.12.025. View

14.

Kim T, Herbst R, Chen L . Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol. 2018; 39(8):624-631. PMC: 6066429. DOI: 10.1016/j.it.2018.05.001. View

15.

Beltran H, Eng K, Mosquera J, Sigaras A, Romanel A, Rennert H . Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol. 2015; 1(4):466-74. PMC: 4505739. DOI: 10.1001/jamaoncol.2015.1313. View

16.

Pogrebniak K, Curtis C . Harnessing Tumor Evolution to Circumvent Resistance. Trends Genet. 2018; 34(8):639-651. PMC: 6368975. DOI: 10.1016/j.tig.2018.05.007. View

17.

Sharma S, Lee D, Li B, Quinlan M, Takahashi F, Maheswaran S . A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141(1):69-80. PMC: 2851638. DOI: 10.1016/j.cell.2010.02.027. View

18.

Menon D, Das S, Krepler C, Vultur A, Rinner B, Schauer S . A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene. 2015; 34(34):4545. DOI: 10.1038/onc.2014.432. View

19.

Dallas N, Xia L, Fan F, Gray M, Gaur P, Van Buren 2nd G . Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009; 69(5):1951-7. PMC: 3198868. DOI: 10.1158/0008-5472.CAN-08-2023. View

20.

Xue Z, Yan H, Li J, Liang S, Cai X, Chen X . Identification of cancer stem cells in vincristine preconditioned SGC7901 gastric cancer cell line. J Cell Biochem. 2011; 113(1):302-12. DOI: 10.1002/jcb.23356. View